{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:15:29Z","timestamp":1790972129205,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jhepr.2023.100874","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T12:10:48Z","timestamp":1691064648000},"page":"100874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-\/- mouse model of sclerosing cholangitis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-1320","authenticated-orcid":false,"given":"Claudia D.","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0251-7196","authenticated-orcid":false,"given":"Natalie","family":"Sroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-006X","authenticated-orcid":false,"given":"Hubert","family":"Scharnagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Minto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Stojakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Liles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Budas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4149-7848","authenticated-orcid":false,"given":"David","family":"Hollenback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100874_bib1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study","volume":"37","author":"de Vries","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100874_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bpg.2011.10.009","article-title":"Pathogenesis of primary sclerosing cholangitis","volume":"25","author":"Pollheimer","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100874_bib3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100874_bib4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100874_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MOG.0b013e32834452c8","article-title":"Farnesoid X receptor agonists for primary biliary cirrhosis","volume":"27","author":"Lindor","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100874_bib6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100874_bib7","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhepr.2023.100874_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100874_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100874_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100874_bib11","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","article-title":"Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC","volume":"21","author":"Trauner","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100874_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: How are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100874_bib13","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep4.1720","article-title":"Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis","volume":"5","author":"John","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2023.100874_bib14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100874_bib15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100874_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ajpath.2014.10.013","article-title":"A new Mdr2(-\/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer","volume":"185","author":"Ikenaga","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2023.100874_bib17","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","article-title":"Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis","volume":"64","author":"Baghdasaryan","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100874_bib18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","article-title":"Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation","volume":"73","author":"Bates","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100874_bib19","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1002\/hep4.2011","article-title":"Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis","volume":"6","author":"Vijayakumar","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2023.100874_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic Effects of the Dual CCR2\/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2023.100874_bib21","doi-asserted-by":"crossref","first-page":"G549","DOI":"10.1152\/ajpgi.00152.2020","article-title":"Bile acid metabolism and circadian rhythms","volume":"319","author":"Yang","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2023.100874_bib22","series-title":"Cilofexor, a Nonsteroidal FXR Agonist Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial","author":"Patel","year":"2020"},{"key":"10.1016\/j.jhepr.2023.100874_bib23","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100874_bib24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100874_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2023.100874_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jcag\/gwy008.199","article-title":"Pharmacodynamic effects of the oral, non-steroidal Farnesoid X receptor agonist GS-9674 in healthy volunteers","volume":"1","author":"Myers","year":"2018","journal-title":"Journal of the Canadian Association of Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100874_bib27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100874_bib28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.1840080429","article-title":"Feedback regulation of bile acid synthesis in the rat by dietary vs. intravenous cholate or taurocholate","volume":"8","author":"Stange","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100874_bib29","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100874_bib30","doi-asserted-by":"crossref","first-page":"eabi4354","DOI":"10.1126\/scitranslmed.abi4354","article-title":"Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis","volume":"14","author":"Shi","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2023.100874_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2249.2000.01356.x","article-title":"Serum interferon-gamma-inducing factor\/IL-18 levels in primary biliary cirrhosis","volume":"122","author":"Yamano","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhepr.2023.100874_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jcmgh.2019.12.008","article-title":"Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct-Ligated Mouse","volume":"9","author":"Cai","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100874_bib33","first-page":"21","article-title":"IL-18 but Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease","author":"Hohenester","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2023.100874_bib34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100874_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010060","article-title":"The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model","volume":"9","author":"Schwabl","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhepr.2023.100874_bib36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","article-title":"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis","volume":"9","author":"Zhou","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jhepr.2023.100874_bib37","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/s41598-020-58562-x","article-title":"Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model","volume":"10","author":"Anfuso","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2023.100874_bib38","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100874_bib39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.30810","article-title":"Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development","volume":"71","author":"Schumacher","year":"2020","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923002057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923002057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:34:49Z","timestamp":1762900489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923002057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2589555923002057"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100874","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-\/- mouse model of sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100874"}}